Haloperidol Lactate

CHEMBL4297147 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

465.9 g/mol

LogP

—

Phase

4

A lactate salt form of haloperidol used in injectable formulations for the rapid treatment of acute psychosis, severe agitation, or delirium in hospital settings. It provides fast-acting antipsychotic and sedating effects when administered intramuscularly or intravenously. This form is preferred for acute interventions due to its rapid onset compared to oral preparations.

분자량

465.9000 g/mol

TPSA

98.10 Å²

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Alzheimer's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Heart Failure Prostate Cancer Colorectal Cancer

작용 기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

기전

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(O)C(=O)O.O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1

InChI

InChI=1S/C21H23ClFNO2.C3H6O3/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16;1-2(4)3(5)6/h3-10,26H,1-2,11-15H2;2,4H,1H3,(H,5,6)

Molecular Formula

C24H29ClFNO5

HBD / HBA

3 / 7

회전 가능 결합

7

무거운 원자

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

A lactate salt form of haloperidol used in injectable formulations for the rapid treatment of acute psychosis, severe agitation, or delirium in hospital settings. It provides fast-acting antipsychotic and sedating effects when administered intramuscularly or intravenously. This form is preferred for acute interventions due to its rapid onset compared to oral preparations.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Haloperidol Lactate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297147. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16051968. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Haloperidol Lactate PillFYI에서

구조

핵심 데이터

분자식: C24H29ClFNO5
동의어: 1

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.